

AngioDynamics Announces Latest Ruling in VNUS Litigation

Trial Date Postponed Due to Busy Court Calendar

QUEENSBURY, N.Y., Oct 23, 2007 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO) announced today that the October 29 trial date in the patent litigation brought by VNUS Medical Technologies against AngioDynamics, Diomed and Vascular Solutions has been postponed due to scheduling conflicts in the court. No new trial date has been set.

Judge Maxine Chesney of the U.S. District Court in the Northern District of California also denied the defendants' motion that two of VNUS's patents are invalid due to prior art, leaving these issues for trial.

In a ruling earlier this month, the Judge denied VNUS's motion for summary judgment of infringement, leaving that issue for trial. The court also denied defendants' motion that another of VNUS' patents was invalid in light of the prior art, as well as the invalidity of all asserted patents for non-compliance with the written description and enablement requirements of the Patent Law, leaving these issues for trial as well.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products.

Safe Harbor

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended June 2, 2007, may affect the actual results achieved by the Company.

SOURCE: AngioDynamics, Inc.

AngioDynamics, Inc.
D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608
jgersuk@AngioDynamics.com
or

EVC Group, Inc.
Jennifer Beugelmans or Doug Sherk, 646-201-5447
(Investor Relations)
jbeugelmans@evcgroup.com
dsherk@evcgroup.com
Steve DiMattia, 646-201-5445 (Media)
sdimattia@evcgroup.com